Home > Boards > US Listed > Biotechs > Bio-Path Holdings Inc. (BPTH)

This news must be the catalyst for the

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
SJSTOCKSHARK Member Profile
 
Followed By 11
Posts 1,588
Boards Moderated 1
Alias Born 09/19/06
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 11/21/2019 8:21:07 AM
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 GlobeNewswire Inc. - 11/21/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/15/2019 7:08:27 AM
Bio-Path Holdings Reports Third Quarter 2019 Financial Results GlobeNewswire Inc. - 11/15/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/14/2019 4:25:09 PM
Bio-Path Holdings to Announce Third Quarter 2019 Financial Results on November 15, 2019 GlobeNewswire Inc. - 11/8/2019 8:00:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 11/1/2019 4:49:22 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 11/1/2019 4:46:18 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 10/22/2019 5:06:33 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/15/2019 4:24:51 PM
Bio-Path Holdings Appoints Martina Molsbergen to Board of Directors GlobeNewswire Inc. - 10/15/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/25/2019 5:17:26 PM
Bio-Path Updates Intellectual Property Portfolio with Addition of Recently Issued Second Platform Technology Patent GlobeNewswire Inc. - 9/25/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/4/2019 4:07:11 PM
Bio-Path Holdings to Present at the H.C. Wainwright 21st Annual Global Investment Conference GlobeNewswire Inc. - 9/3/2019 4:01:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/27/2019 6:02:06 AM
Bio-Path Announces Patient Dosing in Amended Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia GlobeNewswire Inc. - 8/26/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/15/2019 7:06:51 AM
Bio-Path Holdings Reports Second Quarter 2019 Financial Results GlobeNewswire Inc. - 8/15/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/14/2019 4:20:01 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/6/2019 5:07:29 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/6/2019 5:05:06 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 6/6/2019 6:01:49 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/4/2019 4:31:59 PM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 5/16/2019 4:19:14 PM
SJSTOCKSHARK   Tuesday, 09/03/19 04:21:20 PM
Re: None
Post # of 6209 
This news must be the catalyst for the late afternoon surge.

"Bio-Path Holdings to Present at the H.C. Wainwright 21st Annual Global Investment Conference
GLOBENEWSWIRE 1:01 PM ET 9/3/2019
Symbol Last Price Change
BPTH 11.18up +0.07 (+0.63%)
QUOTES AS OF 04:00:00 PM ET 09/03/2019
HOUSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc.(BPTH), , a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter H. Nielsen, Chief Executive Officer, will present a corporate overview at the upcoming H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019 at 3:25 p.m. ET in New York.


A live webcast of the presentation can be accessed under “Events” in the Media section of the Company’s website at www.biopathholdings.com."


Let us hope they raise another 10 million before this stock hits single digits.


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist